Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SANA | Common Stock | Options Exercise | $1.68K | +1.13K | +0.12% | $1.48 | 975K | Sep 1, 2021 | Direct | |
transaction | SANA | Common Stock | Sale | -$28.4K | -1.13K | -0.12% | $25.00 | 974K | Sep 1, 2021 | Direct | F1, F2 |
transaction | SANA | Common Stock | Sale | -$75.1K | -3K | -0.31% | $25.01 | 971K | Sep 1, 2021 | Direct | F1, F3 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SANA | Stock Option (Right to Buy) | Options Exercise | $0 | -1.13K | -0.83% | $0.00 | 135K | Sep 1, 2021 | Common Stock | 1.13K | $1.48 | Direct | F4 |
Id | Content |
---|---|
F1 | The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021. |
F2 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.02, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. |
F3 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.03, inclusive. |
F4 | This option began vesting on February 14, 2020, with 25% of the underlying shares becoming vested and exercisable on February 14, 2021 and the remainder of the underlying shares vesting at a rate of 1/36th per month thereafter. |